A5031869588- Epigenetics and DNA Methylation
- Viral-associated cancers and disorders
- Cancer Cells and Metastasis
- Hedgehog Signaling Pathway Studies
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Cancer Research and Treatments
- ATP Synthase and ATPases Research
- NF-κB Signaling Pathways
- Autophagy in Disease and Therapy
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Medical Imaging and Pathology Studies
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Histiocytic Disorders and Treatments
- CAR-T cell therapy research
- Immune cells in cancer
- Tumors and Oncological Cases
- Vascular Tumors and Angiosarcomas
- Multiple Myeloma Research and Treatments
- Renal cell carcinoma treatment
- Occupational and environmental lung diseases
- Advanced Biosensing Techniques and Applications
UCSF Helen Diller Family Comprehensive Cancer Center
2015-2022
University of California, San Francisco
2015-2022
SRI International
2015
University of Southern California
2012-2014
University of California System
2014
Mutations in Ras family proteins are implicated 33% of human cancers, but direct pharmacological inhibition mutants remains challenging. As an alternative to inhibition, we screened for sensitivities Ras-mutant cells and discovered 249C as a selective cytotoxic agent with nanomolar potency against spectrum cancers. binds vacuolar (V)-ATPase affinity inhibits its activity, preventing lysosomal acidification inhibiting autophagy macropinocytosis pathways that several Ras-driven cancers rely on...
The mechanism of Sonic Hedgehog (Shh) pathway activation in non-small cell lung cancer (NSCLC) is poorly described. Using an antibody against the Shh C-terminal domain, we found a small population Shh-positive (Shh+) cells NSCLC cells. objective this study was to characterize these Shh+ and Shh- were sorted by using Fluorescence Activated Cell Sorting (FACS) on 12 commercial lines. Functional analyses performed with gene expression assays (qRT-PCR microarray) treated cytotoxic chemotherapy...
Background Kaposi’s sarcoma associated herpesvirus encoded viral FLICE inhibitory protein (vFLIP) K13 activates the NF-κB pathway by binding to NEMO/IKKγ subunit of IκB kinase (IKK) complex. However, it has remained enigmatic how K13-NEMO interaction results in activation IKK Recent studies have implicated TRAF6, TAK1 and linear ubiquitin chains assembled a chain assembly complex (LUBAC) consisting HOIL-1, HOIP SHARPIN proinflammatory cytokines. Methodology/Principal Findings Here we...
ABSTRACT Kaposi's sarcoma-associated herpesvirus (KSHV) has been linked to the development of sarcoma, primary effusion lymphoma, and multicentric Castleman's disease (MCD). We have characterized role KSHV-encoded viral FLICE inhibitory protein (vFLIP) K13 in modulation anti-IgM-induced growth arrest apoptosis B cells. demonstrate that protects WEHI 231, an immature B-cell line, against apoptosis. The protective effect was associated with activation NF-κB pathway deficient a mutant three...
ABSTRACT Kaposi's sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 was originally believed to protect virally infected cells against death receptor-induced apoptosis by interfering with caspase 8/FLICE activation. Subsequent studies revealed that also activates the NF-κB pathway binding NEMO/inhibitor of (IκB) kinase gamma (IKKγ) subunit an IKK complex and uses this modulate expression genes involved in cellular survival, proliferation, inflammatory response....
// Hui Li 1, * , Dongsheng Yue 2, Joy Q. Jin 1 Gavitt A. Woodard Bhairavi Tolani Thomas M. Luh Etienne Giroux-Leprieur Minli Mo 3 Zhao Chen Juanjuan Che 4 Zhenfa Zhang 2 Yong Zhou Lei Wang 5 Xishan Hao David Jablons Changli Biao He Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University California, San Francisco, CA 94115, USA Lung Cancer, Tianjin Medical Institute and Hospital, 300060, China Beijing ACCB Biotech Ltd., 100084, Oncology,...
Background Squamous cell carcinomas (SCC) account for approximately 30% of non-small lung cancer (NSCLC). Current staging methods do not adequately predict outcome this disease. EMX2 is a homeo-domain containing transcription factor known to regulate key developmental pathway. This study assessed the significance as prognostic and predictive marker resectable SCC. Methods Two independent cohorts patients with SCC undergoing surgical resection were studied. protein expression was examined by...
The Sonic Hedgehog (Shh) signaling pathway has been implicated in the development and tumor progression of a number human cancers. Using synthetic peptide mimics to mount an immune response, we generated mouse mAb carboxy (C)-terminus Shh protein characterized its preclinical antitumor effects. In vitro screening guided selection best candidate for scale-up production therapeutic development. C-term anti-Shh, Ab 1C11-2G4 was selected based on ELISA screens, Western blotting, flow cytometric...
Despite numerous discoveries regarding the molecular genesis and progression of primary cancers, biology metastasis remains poorly understood. Compared to very large numbers circulating tumor cells that are now known accompany nearly all a relatively limited number lesions actually develop in most patients with metastases. We hypothesized phenotypic changes driven by differential gene expression finite subpopulation render those capable sought identify key pathways through analysis...
Abstract Ovarian cancer is the deadliest gynecological malignancy. Disease recurrence occurs in 70% of patients diagnosed with stage III or IV epithelial ovarian cancer, part due to immune evasion and suppression tumor microenvironment. Tumor infiltration tumor-associated macrophages (TAMs) has been associated poor patient survival TAMs express B7-H4, an orphan ligand that modulates T cell responses. Common features observed microenvironments include hypoxic stress other environmental cues...
ABSTRACT Mutations in the Ras family of oncogenes are implicated 33% human cancers, making an intensely pursued target drug discovery. As alternative to direct pharmacological inhibition Ras, we looked for sensitivities RAS mutant cells. Using a small molecule screen cell lines with mutations and its effector Raf, discovered 249C as Ras-mutant selective cytotoxic agent against spectrum RAS-mutant cancers. By combining CRISPR chemical-genetic screening, comparative profiling chemoproteomics,...